Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-23-027029
Filing Date
2023-06-08
Accepted
2023-06-08 16:33:23
Documents
9
Effectiveness Date
2023-06-08

Document Format Files

Seq Description Document Type Size
1 S-8 rare_2023-06-08-s-8.htm S-8 160018
2 EX-4.4 rare-ex4_4.htm EX-4.4 156399
3 EX-4.5 rare-ex4_5.htm EX-4.5 83833
4 EX-4.7 rare-ex4_7.htm EX-4.7 19060
5 EX-5.1 rare-ex5_1.htm EX-5.1 30623
6 EX-23.1 rare-ex23_1.htm EX-23.1 3717
7 EX-FILING FEES rare-exfiling_fees.htm EX-FILING FEES 37278
8 GRAPHIC img163890588_0.jpg GRAPHIC 35539
9 GRAPHIC img163890588_1.jpg GRAPHIC 35539
  Complete submission text file 0000950170-23-027029.txt   590080
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-272518 | Film No.: 231002415
SIC: 2834 Pharmaceutical Preparations